Rituximab for the first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma
Dundar Y, Bagust A, Hounsome J, McLeod C, Boland A, Davis H, Walley T, Dickson R
Record ID 32011001403
English
Authors' recommendations:
On balance the evidence indicates that R-CVP is more cost-effective than CVP.
Details
Project Status:
Completed
Year Published:
2009
URL for published report:
http://www.hta.ac.uk/1636
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Age Factors
- Antibodies, Monoclonal, Murine-Derived
- Disease-Free Survival
- Male
- Markov Chains
- Middle Aged
- Rituximab
- Technology Assessment, Biomedical
- Antibodies, Monoclonal
- Antineoplastic Combined Chemotherapy Protocols
- Cyclophosphamide
- Lymphoma, Follicular
- Prednisone
- Vincristine
Contact
Organisation Name:
NIHR Health Technology Assessment programme
Contact Address:
NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name:
journals.library@nihr.ac.uk
Contact Email:
journals.library@nihr.ac.uk
Copyright:
2009 Queen's Printer and Controller of HMSO
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.